Back to News & Events

TheraSource LLC receives $3M SBIR Grant

TheraSource LLC, a Feinstein Institute for Medical Research spin-out, has received a $3 million three-year Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health (NIH). The grant will support the development of human ghrelin as an innovative treatment to alleviate health damage caused by unintentional radiation exposure.

TheraSource has been a client of the Center for Biotechnology and the organization is proud to have played an integral role in the helping the company advance their business and technology strategy. As noted by Diane Fabel, Director of Operations for the Center for Biotechnology, “The Phase II award for TheraSource is a significant landmark for the company and an important milestone for the region.”

Ping Wang, MD, founder of TheraSource and Chief of Scientific Officer (CSO) of the Feinstein Institute has stated “Human ghrelin has been investigated in clinical trials of other indications.  With our new findings, we will soon be able to file an Investigational New Drug application to US Food and Drug Administration,” said Dr. Wang. “TheraSource has received investments to fund its various projects and is seeking strategic partnerships towards the goal of clinical development and commercialization.”

For more details, read the company’s press release here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => 
					SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					FROM wp_posts 
					WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					
					ORDER BY RAND()
					LIMIT 0, 3
				
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4285
                    [post_author] => 4
                    [post_date] => 2023-09-11 12:13:16
                    [post_date_gmt] => 2023-09-11 16:13:16
                    [post_content] => 

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3338 [post_author] => 3 [post_date] => 2019-08-26 13:59:23 [post_date_gmt] => 2019-08-26 13:59:23 [post_content] => Due to a few technical difficulties, and to accommodate new and/or incoming awardees, NIH is extending the deadline to apply to their NIH Commercialization Accelerator Program (NIH CAP). The new deadline is 11:59 p.m. PDT (Pacific) FRIDAY, September 13, 2019. This is a cost free* customized commercialization (market readiness/growth) program. For 16 years, CAP has provided customized technical/business assistance to companies at different stages, and has a notable track record: 50 acquisitions (including companies acquired by Sony, Zoll, Bruker, BioMarin, Illumina, Takeda, Google, Roche, etc.), 10 IPOs, and more than $1B in 3rd party funding raised. The program features:
  • world-class guidance from experienced domain professionals, including industry and technical specialists affiliated with Bayer Healthcare, Qualcomm, Baxter, Pfizer, Genetech, McKesson, Medtronic, CMS, Life Technology, etc.
  • Feedback and interaction from a range of stakeholders in the life sciences marketplace
  • Notable graduates of the CAP include: Sharklet, Lift Labs, (provide a few big and recognizable names)
  • Alumni benefit – Continued access to Larta’s network and resources post program!
*CAP participation is free of charge for program participating companies; however, participants are responsible for travel and lodging expenses associated with attending workshops and program related events. For more details on this program, including success data, eligibility and instructions, please visit: https://sbir.nih.gov/cap. [post_title] => DEADLINE EXTENDED! NIH SBIR/STTR Commercialization Accelerator Program (CAP) [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => deadline-extended-nih-cap [to_ping] => [pinged] => [post_modified] => 2019-08-26 13:59:23 [post_modified_gmt] => 2019-08-26 13:59:23 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3338 [menu_order] => 88 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2302 [post_author] => 3 [post_date] => 2016-06-29 14:18:18 [post_date_gmt] => 2016-06-29 14:18:18 [post_content] => Intensity     Intensity Therapeutics has announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices. Lead by President and CEO Lewis H. Bender, the company is developing a proprietary cancer immunotherapy products. In a statement Bender said, “Our lead drug, INT230-6, has shown strong results in severe murine models of metastatic cancer via a combination of direct tumor killing and immune system activation.” According to Bender, “Proceeds will be used to fund operations, manufacture the clinical supplies, permit the needed regulatory filings and conduct a series of clinical trial cohorts in cancer patients with various tumor types.” The company has also announced the addition of Dr. Decalan Doogan former Senior Vice President and Head of worldwide drug development at Pfizer and Emer Leahy, Ph.D., CEO of PsychoGenics will join Intensity’s Board of Directors. More information about Intensity Therapeutics can be found on the company’s website: www.intensitytherapeutics.com. [post_title] => Intensity Therapeutics, Inc. Raises $10 Million Series A [post_excerpt] => Intensity Therapeutics has announced that it has secured $10 million in new capital from a Series A preferred stock financing. Participants included Batterson Venture Capital, VCapital, FastForward Innovations, SalvaRx Group PLC, Declan Doogan M.D. and Jim Mellon as well as several other accredited investors and family offices. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => intensity-therapeutics-inc-raises-10-million-series-a [to_ping] => [pinged] => [post_modified] => 2016-06-29 14:22:19 [post_modified_gmt] => 2016-06-29 14:22:19 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2302 [menu_order] => 174 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 2552 [post_author] => 3 [post_date] => 2017-01-09 15:31:38 [post_date_gmt] => 2017-01-09 15:31:38 [post_content] => Sincerest congratulations to our clients who are being recognized among Stony Brook University's 40 under 40 for 2016.  Since earning their Stony Brook degree, they have gone on to pursue their passions, help others and lead positive change. J. Robert Coleman ’08, PhD Molecular Genetics and Microbiology - Chief Operating Officer, Codagenix, Inc Katarzyna M. Sawicka ’04, ’05, ’14, BS Engineering Chemistry, MS Chemistry, PhD Biomedical Engineering - Founder and President, ImmunoMatrix Joseph Scaduto ’08, MBA Business Administration - Founder and CEO, Traverse Biosciences Inc.
libn40-40Additionally, warmest wishes of continued success to Stony Brook's Director of Government Relations, Lauren Brookmeyer, who was recently named a Long Island Business News "40 under 40 Class of 2017" honoree.   [post_title] => Congratulations 40 under 40 Winners! [post_excerpt] => Three Center for Biotech clients are among the talented individuals recognized as Stony Brook University 's 2016 "40 under 40". [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => congratulations-40-under-40-winners [to_ping] => [pinged] => [post_modified] => 2017-01-09 15:31:38 [post_modified_gmt] => 2017-01-09 15:31:38 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2552 [menu_order] => 155 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4285 [post_author] => 4 [post_date] => 2023-09-11 12:13:16 [post_date_gmt] => 2023-09-11 16:13:16 [post_content] =>

Join Stony Brook University’s Intellectual Property Partners on Thursday, October 12, from 4:30 pm to 6 pm at the Charles B. Wang Center at Stony Brook University for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.”

The event will be hosted by Intellectual Property Partners (IPP), the SBU Chapter of the National Academy of Inventors (NAI), and the Manufacturing and Technology Resource Consortium (MTRC) and will be followed by a networking cocktail reception from 6 pm to 7 pm.

Moderated by Dr. James Hayward, President, CEO and Chairman of Applied DNA Sciences, panelists include:
– Adrian Howansky, PhD, Clinical Medical Physicist, Department of Radiology, Stony Brook University Hospital
– Doreen Swift, Senior Director, Embedded Software Engineering, IPS
– Michael R. Bielski, President, DevTech Partners
– Nariman Boyle, MD, Director, Ophthalmic Plastic Orbit and Reconstructive Surgery, Department of Ophthalmology, Renaissance School of Medicine, Stony Brook University
– Paul Schwartz, Director, Advanced Propulsion Technologies

This event is free and open to Stony Brook University attendees. Space is limited and registration is required. Register here to secure your spot.

For more information visit: https://www.stonybrook.edu/commcms/ipp/Events/Manufacturing.php

[post_title] => "Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing" 10/12/23 [post_excerpt] => Join Stony Brook University’s Intellectual Property Partners on October 12th for the panel discussion titled “Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing.” [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bring-your-new-technology-innovations-to-life-through-prototyping-and-manufacturing-10-12-23 [to_ping] => [pinged] => [post_modified] => 2023-11-15 11:24:35 [post_modified_gmt] => 2023-11-15 16:24:35 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4285 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 249 [max_num_pages] => 83 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

“Bring Your New Technology Innovations to Life Through Prototyping and Manufacturing” 10/12/23

More Information

DEADLINE EXTENDED! NIH SBIR/STTR Commercialization Accelerator Program (CAP)

More Information

Intensity Therapeutics, Inc. Raises $10 Million Series A

More Information

Congratulations 40 under 40 Winners!

More Information